TapewireFind a company

person · Reporting owner

Litvack Frank

Disclosed activity across 1 company

Tapewire entity
47414
SEC CIK
0001310715

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CAPRICOR THERAPEUTICS, INC.CAPR · Entity 5337DirectorMay 13, 2026May 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CAPRICOR THERAPEUTICS, INC.

Report date May 13, 2026 · Filed May 14, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect133,776 Reported balance After 2026-05-13 transaction · row 1
1 source row

Row 1 · 2026-05-13 · Exercise / conversion · Acquired 3,937 · Balance 133,776

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2026-06-02Direct0 Reported balance After 2026-05-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-05-13 · Exercise / conversion · Disposed 3,937 · Balance 0

F2: This option was granted on June 2, 2016 and was previously reported as covering 39,375 shares at an exercise price of $3.12 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020.

F3: 1,750 shares vested immediately on June 2, 2016. The remaining shares vested on December 31, 2016.

Common StockSEC Table I · non-derivativeIndirectHeld in Family Trust46,278 Reported balance Holding disclosure · report date 2026-05-13 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 46,278

F1: Held by Litvack Curtis Family Trust for which the Reporting Person serves as trustee.

Filing footnotes · ownership attribution and instrument terms

F1: Held by Litvack Curtis Family Trust for which the Reporting Person serves as trustee.

F2: This option was granted on June 2, 2016 and was previously reported as covering 39,375 shares at an exercise price of $3.12 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020.

F3: 1,750 shares vested immediately on June 2, 2016. The remaining shares vested on December 31, 2016.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 13, 2026 Filed May 14, 2026 21:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Exercise / conversionStock Option (Right to Buy) · Derivative 3,937 $0.00 Strike: $1.39 $0.00
Disclosure

SEC source: 0001310715-26-000004 · form4-05142026_050501.xml · derivative · entry 3

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,937 shares

Expires 2026-06-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: This option was granted on June 2, 2016 and was previously reported as covering 39,375 shares at an exercise price of $3.12 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020.

F3 · derivative.exercise_date: 1,750 shares vested immediately on June 2, 2016. The remaining shares vested on December 31, 2016.

Read SEC document
May 13, 2026 Filed May 14, 2026 21:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Exercise / conversionCommon Stock 3,937 $1.39 $5,472.43
Disclosure

SEC source: 0001310715-26-000004 · form4-05142026_050501.xml · nonDerivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,776

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 05, 2026 Filed Jan 7, 2026 21:45 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 50,000 $0.00 Strike: $24.81 $0.00
Disclosure

SEC source: 0001310715-26-000002 · form4-01072026_040101.xml · derivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-01-05

F1 · derivative.exercise_date: The shares vest 1/12th of the first day of each month, commencing February 1, 2026, with the last month vesting on December 31, 2026, until the stock option becomes fully vested and exercisable. The award pertains to annual board service as Executive Chairman. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 00:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Exercise / conversionStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $1.39 $0.00
Disclosure

SEC source: 0001415889-25-006736 · form4-03042025_070305.xml · derivative · entry 4

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2025-03-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: This option was granted on March 3, 2015 and was previously reported as covering 250,000 shares at an exercise price of $5.78 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020.

F4 · derivative.exercise_date: Shares vested 1/48th on the first day of each month commencing April 1, 2015.

F3 · derivative.underlying_shares: This option was granted on March 3, 2015 and was previously reported as covering 250,000 shares at an exercise price of $5.78 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 00:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Tax withholdingCommon Stock 2,543 $13.67 $34,762.81
Disclosure

SEC source: 0001415889-25-006736 · form4-03042025_070305.xml · nonDerivative · entry 2

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,839

F1 · kind: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on March 3, 2025 of $13.67. The options would otherwise expire on March 3, 2025, pursuant to their terms.

F1 · price: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on March 3, 2025 of $13.67. The options would otherwise expire on March 3, 2025, pursuant to their terms.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 00:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Exercise / conversionCommon Stock 25,000 $1.39 $34,750.00
Disclosure

SEC source: 0001415889-25-006736 · form4-03042025_070305.xml · nonDerivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,382

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 02, 2025 Filed Jan 7, 2025 00:32 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 50,000 $0.00 Strike: $14.96 $0.00
Disclosure

SEC source: 0001415889-25-000932 · form4-01072025_120110.xml · derivative · entry 3

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2035-01-02

F3 · derivative.exercise_date: The shares vest 1/12th of the first day of each month, commencing February 1, 2025, with the last month vesting on December 31, 2025, until the stock option becomes fully vested and exercisable. The award pertains to annual board service as Executive Chairman. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting.

Read SEC document
December 03, 2024 Filed Dec 5, 2024 01:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Exercise / conversionWarrants (Right to Buy) · Derivative 20,391 $0.00 Strike: $1.10 $0.00
Disclosure

SEC source: 0001415889-24-028337 · form4-12042024_081201.xml · derivative · entry 5

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by Family Trust

Disclosed balance after: 0

Underlying: Common Stock · 20,391 shares

Expires 2024-12-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Held by Litvack Curtis Family Trust for which the Reporting Person serves as trustee.

Read SEC document
December 03, 2024 Filed Dec 5, 2024 01:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Exercise / conversionCommon Stock 20,391 $1.10 $22,430.10
Disclosure

SEC source: 0001415889-24-028337 · form4-12042024_081201.xml · nonDerivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Held in Family Trust

Disclosed balance after: 46,278

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Held by Litvack Curtis Family Trust for which the Reporting Person serves as trustee.

Read SEC document
December 02, 2024 Filed Dec 5, 2024 01:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GiftWarrants (Right to Buy) · Derivative 20,391 $0.00 Strike: $1.10 $0.00
Disclosure

SEC source: 0001415889-24-028337 · form4-12042024_081201.xml · derivative · entry 4

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by Family Trust

Disclosed balance after: 20,391

Underlying: Common Stock · 20,391 shares

Expires 2024-12-17

F1 · ownership.nature: Held by Litvack Curtis Family Trust for which the Reporting Person serves as trustee.

Read SEC document
December 02, 2024 Filed Dec 5, 2024 01:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GiftWarrants (Right to Buy) · Derivative 20,391 $0.00 Strike: $1.10 $0.00
Disclosure

SEC source: 0001415889-24-028337 · form4-12042024_081201.xml · derivative · entry 3

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,391 shares

Expires 2024-12-17

Read SEC document
January 02, 2024 Filed Jan 4, 2024 22:15 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $5.12 $0.00
Disclosure

SEC source: 0001415889-24-000651 · form4-01042024_050108.xml · derivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-01-02

F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing February 1, 2024, until the stock option becomes fully vested and exercisable. The award pertains to annual board service as Executive Chairman. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting.

Read SEC document
August 14, 2023 Filed Aug 16, 2023 21:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Exercise / conversionStock Option (Right to Buy) · Derivative 20,748 $0.00 Strike: $1.39 $0.00
Disclosure

SEC source: 0001415889-23-012326 · form4-08162023_050801.xml · derivative · entry 3

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,748 shares

Expires 2023-08-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: This option was granted on August 21, 2013 and was previously reported as covering 207,485 shares at an exercise price of $0.30 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.

F4 · derivative.exercise_date: The stock option award is fully vested and exercisable.

F3 · derivative.underlying_shares: This option was granted on August 21, 2013 and was previously reported as covering 207,485 shares at an exercise price of $0.30 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.

Read SEC document
August 14, 2023 Filed Aug 16, 2023 21:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Tax withholdingCommon Stock 4,364 $6.61 $28,846.04
Disclosure

SEC source: 0001415889-23-012326 · form4-08162023_050801.xml · nonDerivative · entry 2

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,269

F2 · kind: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on August 14, 2023 of $6.61. The options would otherwise expire on August 21, 2023, pursuant to their terms.

F2 · price: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on August 14, 2023 of $6.61. The options would otherwise expire on August 21, 2023, pursuant to their terms.

Read SEC document
August 14, 2023 Filed Aug 16, 2023 21:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Exercise / conversionCommon Stock 20,748 $1.39 $28,839.72
Disclosure

SEC source: 0001415889-23-012326 · form4-08162023_050801.xml · nonDerivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,633

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount has been adjusted to correct an administrative error in the Form 4 filed by the reporting person on February 23, 2023, which inadvertently overstated the amount of common stock beneficially owned by 20,391 shares.

Read SEC document
February 21, 2023 Filed Feb 23, 2023 14:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Exercise / conversionStock Option (Right to Buy) · Derivative 14,027 $0.00 Strike: $1.39 $0.00
Disclosure

SEC source: 0001415889-23-003083 · form4-02232023_090201.xml · derivative · entry 3

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,027 shares

Expires 2023-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: This option was granted on February 22, 2013 and was previously reported as covering 140,270 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.

F3 · derivative.exercise_date: 25% of the shares vested immediately, with the remainder vesting monthly over 25 months commencing May 1, 2013.

F2 · derivative.underlying_shares: This option was granted on February 22, 2013 and was previously reported as covering 140,270 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.

Read SEC document
February 21, 2023 Filed Feb 23, 2023 14:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Tax withholdingCommon Stock 4,524 $4.31 $19,498.44
Disclosure

SEC source: 0001415889-23-003083 · form4-02232023_090201.xml · nonDerivative · entry 2

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,276

F1 · kind: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on February 21, 2023 of $4.31. The options would otherwise expire on February 22, 2023, pursuant to their terms.

F1 · price: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on February 21, 2023 of $4.31. The options would otherwise expire on February 22, 2023, pursuant to their terms.

Read SEC document
February 21, 2023 Filed Feb 23, 2023 14:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Exercise / conversionCommon Stock 14,027 $1.39 $19,497.53
Disclosure

SEC source: 0001415889-23-003083 · form4-02232023_090201.xml · nonDerivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 03, 2023 Filed Jan 6, 2023 01:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 185,000 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001415889-23-000592 · form4-01052023_080124.xml · derivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,000

Underlying: Common Stock · 185,000 shares

Expires 2033-01-03

F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing February 1, 2023, until the stock option becomes fully vested and exercisable. The award pertains to annual board service as Executive Chairman. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 02:01 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 252,250 $0.00 Strike: $3.18 $0.00
Disclosure

SEC source: 0001415889-22-000284 · form4-01042022_090154.xml · derivative · entry 4

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,250

Underlying: Common Stock · 252,250 shares

Expires 2032-01-03

F3 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing February 1, 2022, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 02:01 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Exercise / conversionStock Option (Right to Buy) · Derivative 154,543 $0.00 Strike: $1.39 $0.00
Disclosure

SEC source: 0001415889-22-000284 · form4-01042022_090154.xml · derivative · entry 3

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 154,543 shares

Expires 2022-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on April 27, 2012 and was previously reported as covering 1,545,435 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 02:01 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Tax withholdingCommon Stock 67,552 $3.18 $214,815.36
Disclosure

SEC source: 0001415889-22-000284 · form4-01042022_090154.xml · nonDerivative · entry 2

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,382

F1 · kind: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on January 3, 2022 of $3.18. The options would otherwise expire on April 27, 2022, pursuant to their terms.

F1 · price: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on January 3, 2022 of $3.18. The options would otherwise expire on April 27, 2022, pursuant to their terms.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 02:01 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Exercise / conversionCommon Stock 154,543 $1.39 $214,814.77
Disclosure

SEC source: 0001415889-22-000284 · form4-01042022_090154.xml · nonDerivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 174,934

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 04, 2021 Filed Jan 6, 2021 22:03 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 211,160 $0.00 Strike: $3.74 $0.00
Disclosure

SEC source: 0001104659-21-001586 · tm211849-4_4seq1.xml · derivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 211,160

Underlying: Common Stock · 211,160 shares

Expires 2031-01-04

F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing February 1, 2021, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting.

Read SEC document
June 05, 2020 Filed Jun 9, 2020 20:34 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 280,935 $0.00 Strike: $1.39 $0.00
Disclosure

SEC source: 0001104659-20-071419 · tm2022128-4_4.xml · derivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,935

Underlying: Common Stock · 280,935 shares

Expires 2030-06-05

F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing March 1, 2020, until the stock option becomes fully vested and exercisable. The following stock option grant was approved by the Board on February 12, 2020 under the 2020 Plan, contingent upon stockholder approval of the 2020 Plan, which was obtained on June 5, 2020. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Disposition to issuerStock Option (Right to Buy) · Derivative 154,543 Not disclosed Strike: $3.70 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 16

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 154,543 shares

Expires 2022-04-27

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F4 · derivative.exercise_date: The stock option award is fully vested and exercisable.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Disposition to issuerStock Option (Right to Buy) · Derivative 14,027 Not disclosed Strike: $3.70 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 15

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,027 shares

Expires 2023-03-06

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F4 · derivative.exercise_date: The stock option award is fully vested and exercisable.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Disposition to issuerStock Option (Right to Buy) · Derivative 20,748 Not disclosed Strike: $3.00 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 14

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,748 shares

Expires 2023-08-21

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F4 · derivative.exercise_date: The stock option award is fully vested and exercisable.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Disposition to issuerStock Option (Right to Buy) · Derivative 25,000 Not disclosed Strike: $57.80 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 13

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2025-03-03

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F4 · derivative.exercise_date: The stock option award is fully vested and exercisable.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Disposition to issuerStock Option (Right to Buy) · Derivative 3,937 Not disclosed Strike: $31.20 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 12

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,937 shares

Expires 2026-06-02

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F4 · derivative.exercise_date: The stock option award is fully vested and exercisable.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Disposition to issuerStock Option (Right to Buy) · Derivative 2,500 Not disclosed Strike: $25.50 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 11

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500 shares

Expires 2027-01-03

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F4 · derivative.exercise_date: The stock option award is fully vested and exercisable.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Disposition to issuerStock Option (Right to Buy) · Derivative 6,000 Not disclosed Strike: $15.70 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 10

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2028-01-02

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F3 · derivative.exercise_date: 3,500 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 2,500 shares will vest 1/12th on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 Disposition to issuerStock Option (Right to Buy) · Derivative 23,750 Not disclosed Strike: $3.25 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 9

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,750 shares

Expires 2029-08-08

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F1 · derivative.exercise_date: 8,000 of the shares were vested on the date of grant. The remaining 15,750 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 154,543 Not disclosed Strike: $1.39 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 8

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,543

Underlying: Common Stock · 154,543 shares

Expires 2022-04-27

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F4 · derivative.exercise_date: The stock option award is fully vested and exercisable.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 14,027 Not disclosed Strike: $1.39 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 7

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,027

Underlying: Common Stock · 14,027 shares

Expires 2023-03-06

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F4 · derivative.exercise_date: The stock option award is fully vested and exercisable.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 20,748 Not disclosed Strike: $1.39 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 6

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,748

Underlying: Common Stock · 20,748 shares

Expires 2023-08-21

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F4 · derivative.exercise_date: The stock option award is fully vested and exercisable.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 25,000 Not disclosed Strike: $1.39 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 5

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2025-03-03

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F4 · derivative.exercise_date: The stock option award is fully vested and exercisable.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 3,937 Not disclosed Strike: $1.39 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 4

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,937

Underlying: Common Stock · 3,937 shares

Expires 2026-06-02

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F4 · derivative.exercise_date: The stock option award is fully vested and exercisable.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 2,500 Not disclosed Strike: $1.39 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 3

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

Underlying: Common Stock · 2,500 shares

Expires 2027-01-03

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F4 · derivative.exercise_date: The stock option award is fully vested and exercisable.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 6,000 Not disclosed Strike: $1.39 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 2

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2028-01-02

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F3 · derivative.exercise_date: 3,500 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 2,500 shares will vest 1/12th on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:08 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (Right to Buy) · Derivative 23,750 Not disclosed Strike: $1.39 Not disclosed
Disclosure

SEC source: 0001104659-20-022101 · tm208086d4_4.xml · derivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,750

Underlying: Common Stock · 23,750 shares

Expires 2029-08-08

F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.

F1 · derivative.exercise_date: 8,000 of the shares were vested on the date of grant. The remaining 15,750 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.

Read SEC document
December 17, 2019 Filed Dec 20, 2019 00:35 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantWarrants (Right to Buy) · Derivative 20,391 Not disclosed Strike: $1.10 Not disclosed
Disclosure

SEC source: 0001104659-19-074516 · tm1926719d3_4.xml · derivative · entry 2

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,391

Underlying: Common Stock · 20,391 shares

Expires 2024-12-17

F1 · price: The Reporting Person on December 17, 2019, purchased 20,391 shares of the common stock of Capricor Therapeutics, Inc. (the "Issuer"), and accompanying amount of warrants to purchase up to an aggregate of 20,391 shares of the Issuer's common stock, at a combined purchase price of $1.226 per share of common stock and accompanying warrant, for a total cost of approximately US$25,000.

Read SEC document
December 17, 2019 Filed Dec 20, 2019 00:35 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantCommon Stock 20,391 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-19-074516 · tm1926719d3_4.xml · nonDerivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,391

F1 · price: The Reporting Person on December 17, 2019, purchased 20,391 shares of the common stock of Capricor Therapeutics, Inc. (the "Issuer"), and accompanying amount of warrants to purchase up to an aggregate of 20,391 shares of the Issuer's common stock, at a combined purchase price of $1.226 per share of common stock and accompanying warrant, for a total cost of approximately US$25,000.

Read SEC document
August 08, 2019 Filed Aug 10, 2019 01:00 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (right to buy) · Derivative 23,750 $0.00 Strike: $3.25 $0.00
Disclosure

SEC source: 0001144204-19-039001 · tv527332_form4.xml · derivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,750

Underlying: Common Stock · 23,750 shares

Expires 2029-08-08

F1 · derivative.exercise_date: 8,000 of the shares shall vest immediately. The remaining 15,750 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.

Read SEC document
January 02, 2018 Filed Jan 4, 2018 22:02 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (right to buy) · Derivative 60,000 $0.00 Strike: $1.57 $0.00
Disclosure

SEC source: 0001144204-18-000859 · tv482716_4.xml · derivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2028-01-02

F1 · derivative.exercise_date: 35,000 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 25,000 shares will vest 1/12 on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.

Read SEC document
January 03, 2017 Filed Jan 5, 2017 02:42 UTC CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $2.55 $0.00
Disclosure

SEC source: 0001144204-17-000702 · v456177_4.xml · derivative · entry 1

Litvack Frank · CIK 0001310715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2027-01-03

F1 · derivative.exercise_date: 25,000 shares will vest 1/12 on the first day of each month, commencing February 1, 2017, with the last month vesting on December 31, 2017, until the stock option becomes fully vested and exercisable. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.